Stay updated with breaking news from Iddo Heller. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- In its effort to develop effective cellular immunotherapies for cancer treatment, the Regensburg Center for Interventional Immunology (RCI) in...
Regensburg Center for Interventional Immunology adopts LUMICKS’ z-Movi® Cell Avidity Analyzer Amsterdam, the Netherlands – May 27, 2021 – In its effort to develop effective cellular immunotherapies for cancer treatment, the Regensburg Center for Interventional Immunology (RCI) in Germany has purchased LUMICKS’ z-Movi® Cell Avidity Analyzer. The placement highlights the promise of measuring cell avidity between immune cells and their tumor targets to improve the selection of chimeric antigen receptors (CARs) and accelerate the development of new CAR-T therapies. The new instrument h...
Lumicks, an Amsterdam, The Netherlands-based life science tools company that develops innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, closed a $93m Series D funding. The round was led by new investors Farallon Capital Management and Lauxera Capital Partners, with participation from Softbank Vision 2, funds and accounts advised by T. Rowe Price Associates, Parian Global Management, Pura Vida Investments, and Irving Investors, as well as existing investor Gilde Healthcare and select members of the management team. The company intends to use the funds to accelerate...
LUMICKS Raises $93 Million in Series D Financing - Backed by global investor syndicate led by new investors Farallon Capital Management and Lauxera Capital Partners along with Softbank Fund 2, funds and accounts advised by T. Rowe Price Associates, Parian Global Management, Gilde Healthcare, Pura Vida Investments, and Irving Investors AMSTERDAM, April 16, 2021 /PRNewswire/ -- LUMICKS, a leading, next-generation life science tools company that develops highly innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, announced the completion of a $93 million Series D preferred...